financetom
Business
financetom
/
Business
/
Top Premarket Decliners
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Top Premarket Decliners
Mar 8, 2024 5:14 AM

07:54 AM EST, 03/08/2024 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) shares slumped 80% Friday premarket after the company said its phase 3 study of a potential treatment of amyotrophic lateral sclerosis failed to meet its primary endpoint.

AerSale ( ASLE ) shares fell 20% after the company reported weaker Q4 financial results.

BigBear.ai ( BBAI ) shares retreated 19% after the company reported Q4 results that trailed analysts' estimates.

Genesco ( GCO ) shares were down 12% after the company reported lower fiscal Q4 earnings.

Price: 3.75, Change: -15.22, Percent Change: -80.23

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Wells Fargo Adjusts Martin Marietta Materials PT to $610 From $620, Maintains Equalweight Rating
--Wells Fargo Adjusts Martin Marietta Materials PT to $610 From $620, Maintains Equalweight Rating
Nov 6, 2025
11:34 AM EST, 11/06/2025 (MT Newswires) -- Price: 604.91, Change: -5.70, Percent Change: -0.93 ...
Johnson Controls' Order Growth, Profit Leverage Drive Upbeat Outlook, UBS Says
Johnson Controls' Order Growth, Profit Leverage Drive Upbeat Outlook, UBS Says
Nov 6, 2025
11:35 AM EST, 11/06/2025 (MT Newswires) -- Johnson Controls International ( JCI ) reported encouraging fiscal Q4 results, with solid order growth, a rising backlog and higher profit leverage that prompted the company to issue fiscal 2026 guidance above Wall Street expectations, UBS Securities said in a report emailed Thursday. Organic orders rose 6% in the latest quarter, accelerating from...
Genmab's Q3 Net Profit, Revenue Increase; 2025 Revenue Outlook Maintained
Genmab's Q3 Net Profit, Revenue Increase; 2025 Revenue Outlook Maintained
Nov 6, 2025
11:32 AM EST, 11/06/2025 (MT Newswires) -- Genmab ( GMAB ) reported a Q3 net profit Thursday of $6.46 per diluted share, up from $2.92 a year earlier. Analysts polled by FactSet expected $4.86. Revenue for the quarter ended Sept. 30 was $1.02 billion, compared with $816 million a year earlier. Analysts polled by FactSet expected $990.4 million. The company...
Snap Faces User Growth Uncertainty Amid Age Verification Rollout, Morgan Stanley Says
Snap Faces User Growth Uncertainty Amid Age Verification Rollout, Morgan Stanley Says
Nov 6, 2025
11:34 AM EST, 11/06/2025 (MT Newswires) -- Snap (SNAP) delivered Q3 results ahead of Morgan Stanley's expectations, but its forward user growth faces uncertainty as new age verification rules roll out, and its revenue growth is still not outstanding compared with peers, the investment firm said in a note Thursday. Snap's Q3 performance was supported by better forward profitability and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved